Skye Bioscience, Inc. Common Stock Cash Flow Conversion Efficiency
Skye Bioscience, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Skye Bioscience, Inc. Common Stock (SKYE) has a cash flow conversion efficiency ratio of 14.320x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.12 Million) by net assets ($-497.31K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Skye Bioscience, Inc. Common Stock (2012–2025)
Cash flow conversion efficiency of Skye Bioscience, Inc. Common Stock from 2012 to 2025. This chart illustrates how Skye Bioscience, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Skye Bioscience, Inc. Common Stock (SKYE) stock price for real-time trading data and today's change.
Skye Bioscience, Inc. Common Stock Cash Flow Conversion Ratio Explained
Skye Bioscience, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Skye Bioscience, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Skye Bioscience, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Skye Bioscience, Inc. Common Stock (SKYE) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Robogroup
TA:ROBO
|
-0.260x |
|
DB ENERGY S.A. ZY -10
F:0CJ
|
-0.016x |
|
CN Asia Corporation Bhd
KLSE:7986
|
0.017x |
|
Prolexus Bhd
KLSE:8966
|
-0.039x |
|
Proodeftiki S.A.
AT:PRD
|
-0.022x |
|
5E ADVANCED MATERIALS CDI
F:J9I0
|
-0.101x |
|
Ferguson Plc
LSE:FERG
|
0.132x |
|
Palamina Corp
V:PA
|
-1.095x |
Annual Cash Flow Conversion Efficiency for Skye Bioscience, Inc. Common Stock (2012–2025)
The table below shows the annual cash flow conversion efficiency of Skye Bioscience, Inc. Common Stock from 2012 to 2025. Review Skye Bioscience, Inc. Common Stock (SKYE) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.02 Million | $-43.06 Million | -2.151x | -480.73% |
| 2024-12-31 | $68.15 Million | $-25.24 Million | -0.370x | -105.66% |
| 2023-12-31 | $-2.13 Million | $-13.95 Million | 6.545x | +54.48% |
| 2022-12-31 | $-3.01 Million | $-12.74 Million | 4.237x | +483.70% |
| 2021-12-31 | $5.86 Million | $-6.47 Million | -1.104x | +91.78% |
| 2020-12-31 | $450.79K | $-6.05 Million | -13.430x | -22.11% |
| 2019-12-31 | $548.06K | $-6.03 Million | -10.999x | -4440.97% |
| 2018-12-31 | $-15.56 Million | $-3.94 Million | 0.253x | -93.85% |
| 2017-12-31 | $-800.08K | $-3.30 Million | 4.122x | +68.34% |
| 2016-12-31 | $-1.45 Million | $-3.55 Million | 2.449x | +130.94% |
| 2015-12-31 | $471.00K | $-3.73 Million | -7.915x | -304.53% |
| 2014-12-31 | $-453.55K | $-1.76 Million | 3.870x | +873.40% |
| 2013-12-31 | $-36.46K | $-14.49K | 0.398x | +695.12% |
| 2012-12-31 | $38.56K | $1.93K | 0.050x | -- |
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1… Read more